HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $180 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Axsome Therapeutics (NASDAQ:AXSM) and maintained a price target of $180.
March 20, 2024 | 10:46 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Axsome Therapeutics receives a reiterated Buy rating and a maintained $180 price target from HC Wainwright & Co.
The reiteration of a Buy rating and maintenance of a high price target by a reputable analyst firm like HC Wainwright & Co. typically signals strong confidence in the company's future performance. This endorsement is likely to positively influence investor sentiment and could lead to a short-term uptick in AXSM's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100